Menu Search
Equities

InVivo Therapeutics Holdings Corp

04I:BER

InVivo Therapeutics Holdings Corp

Actions
  • Price (EUR)0.36
  • Today's Change-0.006 / -1.64%
  • Shares traded2.00k
  • 1 Year change-67.33%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 14:36 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCIs). The Company's Neuro-Spinal Scaffold implant is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. It is intended to promote appositional, or side-by-side, healing by supporting the surrounding tissue after injury, minimizing the expansion of areas of necrosis, and providing a biomaterial substrate for the body's own healing/repair processes following injury. It is composed of two biocompatible and bioresorbable polymers that are cast to form a porous investigational product: Poly lactic-co-glycolic acid and Poly-L-Lysine. Poly lactic-co-glycolic acid is a polymer that is used in resorbable sutures and provides biocompatible support for Neuro-Spinal Scaffold implants and Poly-L-Lysine is a positively charged polymer used to coat surfaces.

  • Revenue in USD (TTM)0.00
  • Net income in USD-9.33m
  • Incorporated2003
  • Employees6.00
  • Location
    InVivo Therapeutics Holdings CorpBuilding 1400 East 4Th FloorOne Kendall SquareCAMBRIDGE 02139United StatesUSA
  • Phone+1 (617) 863-5524
  • Websitehttps://www.invivotherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.